These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Falagas ME; Snydman DR; Griffith J; Ruthazer R; Werner BG Ann Intern Med; 1997 Feb; 126(4):275-9. PubMed ID: 9036799 [TBL] [Abstract][Full Text] [Related]
23. Incidence of cytomegalovirus infections in renal transplant patients treated with conventional or cyclosporin therapy. Guerin C; Pozzetto B; Genin C; Berthoux FC; Gaudin OG Nephrol Dial Transplant; 1988; 3(1):77-80. PubMed ID: 2837679 [TBL] [Abstract][Full Text] [Related]
24. Cytomegalovirus infection and disease in renal transplant patients treated with cyclosporin. A prospective study. Bosch FH; Hoitsma AJ; Janssen HP; van Loon AM; Koene RA Transpl Int; 1989 Aug; 2(2):92-5. PubMed ID: 2551314 [TBL] [Abstract][Full Text] [Related]
25. Interferon-gamma gene polymorphism +874 A/T is associated with an increased risk of cytomegalovirus infection among Hispanic renal transplant recipients. Vu D; Shah T; Ansari J; Sakharkar P; Yasir Q; Naraghi R; Hutchinson I; Min D Transpl Infect Dis; 2014 Oct; 16(5):724-32. PubMed ID: 25208755 [TBL] [Abstract][Full Text] [Related]
26. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). Hassan-Walker AF; Kidd IM; Sabin C; Sweny P; Griffiths PD; Emery VC J Med Virol; 1999 Jun; 58(2):182-7. PubMed ID: 10335868 [TBL] [Abstract][Full Text] [Related]
28. Panresistant cytomegalovirus in a kidney transplant recipient. Yost SE; Echeverria A; Jie T; Kaplan B Pharmacotherapy; 2014 Jan; 34(1):e1-3. PubMed ID: 24277702 [TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus disease in a renal transplant recipient: the importance of pre-transplant screening of the donor and recipient. Mitwalli AH; Nazmi A; Al Ghonaim M; Shaheen F; Kfoury H Saudi J Kidney Dis Transpl; 2013 Jan; 24(1):80-5. PubMed ID: 23354197 [TBL] [Abstract][Full Text] [Related]
30. The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival. Smedbråten YV; Sagedal S; Leivestad T; Mjøen G; Osnes K; Rollag H; Reisaeter AV; Foss A; Os I; Hartmann A Clin Transplant; 2014 Jan; 28(1):120-6. PubMed ID: 24351078 [TBL] [Abstract][Full Text] [Related]
31. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients. Stratta RJ; Alloway RR; Lo A; Hodge EE; Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376 [TBL] [Abstract][Full Text] [Related]
32. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Sagedal S; Hartmann A; Nordal KP; Osnes K; Leivestad T; Foss A; Degré M; Fauchald P; Rollag H Kidney Int; 2004 Jul; 66(1):329-37. PubMed ID: 15200441 [TBL] [Abstract][Full Text] [Related]
33. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Smiley ML; Wlodaver CG; Grossman RA; Barker CF; Perloff LJ; Tustin NB; Starr SE; Plotkin SA; Friedman HM Transplantation; 1985 Aug; 40(2):157-61. PubMed ID: 2992130 [TBL] [Abstract][Full Text] [Related]
35. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression. Shah AP; Chen JM; Fridell JA Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498 [TBL] [Abstract][Full Text] [Related]
36. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease. Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637 [TBL] [Abstract][Full Text] [Related]
37. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246 [TBL] [Abstract][Full Text] [Related]
38. Cytomegalo and herpes simplex virus infections in renal transplant recipients. Wertheim P; Slaterus KW; Geelen JL; van der Noordaa J; Wilmink JM Scand J Urol Nephrol Suppl; 1985; 92():5-8. PubMed ID: 3008317 [TBL] [Abstract][Full Text] [Related]
39. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744 [TBL] [Abstract][Full Text] [Related]